NCT02238522

Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML

Phase 1 Open-label Dose Escalation and Expansion Study of ZEN003365 in Subjects With Relapsed or Refractory Lymphoproliferative Malignancies or Acute Myeloid Leukemia

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Zenith Epigenetics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine safety, tolerability, dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory lymphoproliferative malignancies (LPM) or relapsed/refractory acute myeloid leukemia (AML).

Conditions

• Lymphoproliferative Malignancies
• Acute Myeloid Leukemia

Interventions

Type	Name	Description
DRUG	ZEN003365

Timeline

• Start date: 2014-10-01
• Primary completion: 2016-06-01
• Completion: 2017-01-01
• First posted: 2014-09-12
• Last updated: 2014-11-13

Locations

4 sites across 1 country: United States